Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Depreciation & Amortization (CF) (2023 - 2025)

CG Oncology's Depreciation & Amortization (CF) history spans 3 years, with the latest figure at $849000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed N/A year-over-year to $849000.0; the TTM value through Dec 2025 reached $1.4 million, up 4415.62%, while the annual FY2025 figure was $1.4 million, 4415.62% up from the prior year.
  • Depreciation & Amortization (CF) reached $849000.0 in Q4 2025 per CGON's latest filing, up from $416000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $849000.0 in Q4 2025 to a low of $4000.0 in Q1 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $135818.2, with a median of $7000.0 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): changed 0.0% in 2024, then soared 2128.57% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $4000.0 in 2023, then skyrocketed by 425.0% to $21000.0 in 2024, then surged by 3942.86% to $849000.0 in 2025.
  • Per Business Quant, the three most recent readings for CGON's Depreciation & Amortization (CF) are $849000.0 (Q4 2025), $416000.0 (Q3 2025), and $156000.0 (Q2 2025).